Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

2.7.7.48: RNA-directed RNA polymerase

This is an abbreviated version!
For detailed information about RNA-directed RNA polymerase, go to the full flat file.

Word Map on EC 2.7.7.48

Reaction

nucleoside triphosphate
+
RNAn
=
diphosphate
 +
RNAn+1

Synonyms

111 kDa protein, 180 kDa protein, 182 kDa protein, 183 kDa protein, 186 kDa protein, 216.5 kDa protein, 2A protein, 3CD protein, 3D pol, 3D polymerase, 3Dpol, 3Dpol-like protein, 3P complex, 69.6 kDa protein, core protein, core protein VP1, CVB3 RdRp, D-elp1, DENV 3 polymerase, DENV 3 RdRp, DENV RdRp, ego-1, ego-11, FluPol, FMDV 3D, GhRdRP, HC-J4 NS5BDELTA21, HCN NS5B protein, HCV NS5B, HCV NS5B polymerase, HCV RdRp, hepatitis C virus polymerase, HRV16 3Dpol, influenza polymerase PA, inner layer protein VP1, JEV NS5, JEV NS5 protein, JEV RdRp, jRdRp, L protein, L/P RdRP, large structural protein, M1 phosphoprotein, MOP1, More, NgRDR1, NIB, nonstructural phosphoprotein, nonstructural protein, nonstructural protein 12, nonstructural protein 5B, NS5, NS5 polymerase, NS5 protein, NS5 RdRp, NS5B, NS5B enzyme, NS5B polymerase, NS5B protein, NS5B RdRp, NS5B RNA-dependent RNA polymerase, NS5b-directed RNA polymerase, NS7, nsp12, nsp4, nucleocapsid phosphoprotein, nucleotidyltransferase, ribonucleate, RNA-dependent, ORF1, ORF1A, ORF1B, OsRDR6, P protein, P180, P3D, P66, P70, P88 protein, p92, PB1, PB1 proteins, PB2, PB2 proteins, Phage f2 replicase, phi6, phi6 polymerase, picornaviral 3D polymerase, plant-encoded RNA-dependent RNA polymerase 1, Pol, Pol IV, polymerase 3Dpol, polymerase acidic protein, polymerase basic 1 protein, polymerase L, protein 3Dpol, proteins PB1, proteins, PB 2, proteins, specific or class, lambda3, of reovirus, proteins, specific or class, PB 1, proteins, specific or class, PB 2, Q-beta replicase, Qbeta replicase, Qbeta-replicase, RDR, RDR1, RDR1a, RDR1b, RDR1c, RDR1c2, RDR2, RDR6, RDRP, replicase, phage f2, replicase, Qbeta, ribonucleic acid replicase, ribonucleic acid-dependent ribonucleate nucleotidyltransferase, ribonucleic acid-dependent ribonucleic acid polymerase, ribonucleic replicase, ribonucleic synthetase, RNA dependent RNA polymerase, RNA nucleotidyltransferase (RNA-directed), RNA polymerase, RNA polymerase IV, RNA replicase, RNA synthetase, RNA transcriptase, RNA-binding protein, RNA-dependent ribonucleate nucleotidyltransferase, RNA-dependent RNA polymerase, RNA-dependent RNA polymerase 1, RNA-Dependent RNA Polymerase 2, RNA-dependent RNA polymerase 6, RNA-dependent RNA polymerase NIb, RNA-dependent RNA polymerase NS5B, RNA-dependent RNA polymerases, RNA-dependent RNA replicase, RNA-dependent RNA-polymerase, RNA-directed RNA polymerase, RNA-directed RNA polymerase L, RNAdependent RNA polymerase, rrf-1, RRF-3, RrpC, RSV RdRp, SARS-CoV-2 RdRp, SARS-CoV-2 RNA polymerase, SARSCoV-2 polymerase, SARSCoV-2-core polymerase complex, self-priming RdRp, sigma NS protein, transcriptase, VP1, VP1 protein, WNV NS5

ECTree

     2 Transferases
         2.7 Transferring phosphorus-containing groups
             2.7.7 Nucleotidyltransferases
                2.7.7.48 RNA-directed RNA polymerase

Inhibitors

Inhibitors on EC 2.7.7.48 - RNA-directed RNA polymerase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(1R)-6-bromo-N-[(1S)-1-phenylethyl]-2,3,4,9-tetrahydro-1H-carbazol-1-amine
-
-
(1S)-1-(4-aminofuro[3,2-d]pyrimidin-7-yl)-1,4-anhydro-2-C-methyl-D-ribitol
-
-
(1S)-1-(4-aminothieno[3,2-d]pyrimidin-7-yl)-1,4-anhydro-2-C-methyl-D-ribitol
-
-
(2E)-3-(4-[[(1-[[(1-cyclohexyl-2-furan-3-yl-1H-benzimidazol-5-yl)carbonyl]amino]cyclobutyl)carbonyl]amino]phenyl)prop-2-enoic acid
-
-
(2E)-3-(4-[[(2-cyclohexyl-3-phenylquinoxalin-6-yl)carbonyl]amino]phenyl)prop-2-enoic acid
-
(2E)-3-[4-([[1-([[2,3-bis(4-fluorophenyl)quinoxalin-6-yl]carbonyl]amino)cyclobutyl]carbonyl]amino)phenyl]prop-2-enoic acid
-
(2E)-3-[4-([[1-([[2,3-bis(4-fluorophenyl)quinoxalin-6-yl]carbonyl]amino)cyclopentyl]carbonyl]amino)phenyl]prop-2-enoic acid
-
(2E)-3-[4-([[1-([[2-cyclohexyl-3-(4-fluorophenyl)quinoxalin-6-yl]carbonyl]amino)cyclobutyl]carbonyl]amino)phenyl]prop-2-enoic acid
-
(2E)-3-[4-([[1-([[3-cyclohexyl-2-(4-fluorophenyl)quinoxalin-6-yl]carbonyl]amino)cyclobutyl]carbonyl]amino)phenyl]prop-2-enoic acid
-
(2E)-3-[4-([[2,3-bis(4-fluorophenyl)quinoxalin-6-yl]carbonyl]amino)phenyl]prop-2-enoic acid
-
(2E)-3-[4-([[2-cyclohexyl-3-(4-fluorophenyl)quinoxalin-6-yl]carbonyl]amino)phenyl]prop-2-enoic acid
-
(2E)-3-[4-([[3-cyclohexyl-2-(4-fluorophenyl)quinoxalin-6-yl]carbonyl]amino)phenyl]prop-2-enoic acid
-
(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-2-azido-2-[[(2-methylpropanoyl)oxy]methyl]tetrahydrofuran-3,4-diyl bis(2-methylpropanoate)
-
-
(2R,3S,5S)-5-(methoxycarbonyl)-5-(2-methylpropyl)-2-thiophen-2-yl-1-[[4-(trifluoromethyl)phenyl]carbonyl]pyrrolidine-3-carboxylic acid
-
-
(2R,3S,5S)-5-[(aminooxy)carbonyl]-5-(2-methylpropyl)-2-thiophen-2-yl-1-[[4-(trifluoromethyl)phenyl]carbonyl]pyrrolidine-3-carboxylic acid
-
-
(2S)-(((5Z)-5-[(5-ethyl-2-furyl)methylene]-4-oxo-4,5-dihydro-1,3-thiazol-2-yl)amino)(4-fluorophenyl)acetic acid
-
-
(2S)-1-[(2-amino-4-chloro-5-methylphenyl)sulfonyl]pyrrolidine-2-carboxylic acid
-
-
(2S)-1-[(3,4,5-trichloro-2-hydroxyphenyl)sulfonyl]pyrrolidine-2-carboxylic acid
-
-
(2S)-1-[(3,5-dichloro-2-hydroxyphenyl)sulfonyl]pyrrolidine-2-carboxylic acid
-
-
(2S)-1-[[4-([[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]carbonyl]amino)phenyl]sulfonyl]pyrrolidine-2-carboxylic acid
-
-
(2S)-2-[(2,4-dichlorobenzoyl)(3-nitrobenzyl)amino]-3-phenylpropanoic acid
-
-
(2S,4S,5R)-1-[(4-tert-butylphenyl)carbonyl]-2-(2-methylpropyl)-5-(1,3-thiazol-2-yl)pyrrolidine-2,4-dicarboxylic acid
-
-
(2S,4S,5R)-1-[(4-tert-butylphenyl)carbonyl]-2-(2-methylpropyl)-5-thiophen-2-ylpyrrolidine-2,4-dicarboxylic acid
-
-
(2S,4S,5R)-2-(2-methylpropyl)-5-(1,3-thiazol-2-yl)-1-[[4-(trifluoromethyl)phenyl]carbonyl]pyrrolidine-2,4-dicarboxylic acid
-
-
(2S,4S,5R)-2-(2-methylpropyl)-5-thiophen-2-yl-1-[[4-(trifluoromethyl)phenyl]carbonyl]pyrrolidine-2,4-dicarboxylic acid
-
-
(2S,4S,5R)-2-isobutyl-4-(2-phenylacetyl)-5-(thiophen-2-yl)-1-(4-(trifluoromethyl)benzoyl)pyrrolidine-2-carboxylic acid
-
-
(2S,4S,5R)-2-isobutyl-5-(thiophen-2-yl)-1-(4-(trifluoromethyl)benzoyl)pyrrolidine-2,4-dicarboxylic acid
-
-
(2S,4S,5R)-4-acetyl-2-isobutyl-5-(thiophen-2-yl)-1-(4-(trifluoromethyl)benzoyl)pyrrolidine-2-carboxylic acid
-
-
(2S,5R)-1-[(4-tert-butylphenyl)carbonyl]-2-(2-methylpropyl)-5-(1,3-thiazol-2-yl)-2,5-dihydro-1H-pyrrole-2,4-dicarboxylic acid
-
-
(2Z)-2-(benzoylamino)-3-(5-phenyl-2-furyl)acrylic acid
-
-
(2Z)-2-(benzoylamino)-3-[4-(2-bromophenoxy)phenyl]acrylic acid
-
-
(2Z)-3-[4-([[1-([[2-cyclohexyl-3-(4-fluorophenyl)quinoxalin-6-yl]carbonyl]amino)cyclobutyl]carbonyl]amino)phenyl]prop-2-enoic acid
-
(2Z)-3-[4-([[1-([[3-cyclohexyl-2-(4-fluorophenyl)quinoxalin-6-yl]carbonyl]amino)cyclobutyl]carbonyl]amino)phenyl]prop-2-enoic acid
-
(4E)-1-(3,4-dimethylphenyl)-4-(hydroxyimino)pyrazolidine-3,5-dione
-
(4R,5R)-1-[(4-tert-butyl-3-methoxyphenyl)carbonyl]-4-(ethoxymethyl)-2-(2-methylpropyl)-5-(1,3-thiazol-2-yl)-L-proline
-
-
(4R,5R)-1-[(4-tert-butyl-3-methoxyphenyl)carbonyl]-4-(hydroxymethyl)-2-(2-methylpropyl)-5-(1,3-thiazol-2-yl)-L-proline
-
-
(4S,5R)-1-[(3-bromo-4-tert-butylphenyl)carbonyl]-4-carbamoyl-2-(2-methylpropyl)-5-(1,3-thiazol-2-yl)-L-proline
-
-
(4S,5R)-1-[(4-tert-butyl-3-chlorophenyl)carbonyl]-4-carbamoyl-2-(2-methylpropyl)-5-(1,3-thiazol-2-yl)-L-proline
-
-
(4S,5R)-1-[(4-tert-butyl-3-methoxyphenyl)carbonyl]-4-(ethoxymethyl)-2-(2-methylpropyl)-5-(1,3-thiazol-2-yl)-L-proline
-
-
(4S,5R)-1-[(4-tert-butyl-3-methoxyphenyl)carbonyl]-4-(hydroxymethyl)-2-(2-methylpropyl)-5-(1,3-thiazol-2-yl)-L-proline
-
-
(4S,5R)-1-[(4-tert-butyl-3-methoxyphenyl)carbonyl]-4-(methoxymethyl)-2-(2-methylpropyl)-5-(1,3-thiazol-2-yl)-L-proline
-
-
(4S,5R)-1-[(4-tert-butyl-3-methoxyphenyl)carbonyl]-4-carbamoyl-2-(2-methylpropyl)-5-(1,3-thiazol-2-yl)-L-proline
-
-
(4S,5R)-1-[(4-tert-butyl-3-methoxyphenyl)carbonyl]-4-methoxy-2-(2-methylpropyl)-5-(1,3-thiazol-2-yl)-L-proline
-
-
(4S,5R)-1-[(4-tert-butylphenyl)carbonyl]-2-(2-methylpropyl)-4-(phenylcarbamoyl)-5-(1,3-thiazol-2-yl)-L-proline
-
-
(4S,5R)-1-[(4-tert-butylphenyl)carbonyl]-2-(2-methylpropyl)-4-[[(2-phenylethoxy)sulfinyl]carbamoyl]-5-(1,3-thiazol-2-yl)-L-proline
-
-
(4S,5R)-1-[(4-tert-butylphenyl)carbonyl]-4-(methylcarbamoyl)-2-(2-methylpropyl)-5-(1,3-thiazol-2-yl)-L-proline
-
-
(4S,5R)-1-[(4-tert-butylphenyl)carbonyl]-4-carbamoyl-2-(2-methylpropyl)-5-(1,3-thiazol-2-yl)-L-proline
-
-
(4S,5R)-1-[(4-tert-butylphenyl)carbonyl]-4-carbamoyl-2-(2-methylpropyl)-5-thiophen-2-yl-L-proline
-
-
(4S,5R)-1-[(4-tert-butylphenyl)carbonyl]-4-[(methoxysulfinyl)carbamoyl]-2-(2-methylpropyl)-5-(1,3-thiazol-2-yl)-L-proline
-
-
(4S,5R)-2-(2-methylpropyl)-4-(phenylcarbamoyl)-5-thiophen-2-yl-1-[[4-(trifluoromethyl)phenyl]carbonyl]-L-proline
-
-
(4S,5R)-2-(2-methylpropyl)-4-[(2-phenylethyl)carbamoyl]-5-thiophen-2-yl-1-[[4-(trifluoromethyl)phenyl]carbonyl]-L-proline
-
-
(4S,5R)-2-(2-methylpropyl)-5-thiophen-2-yl-4-[[(trifluoromethoxy)sulfinyl]carbamoyl]-1-[[4-(trifluoromethyl)phenyl]carbonyl]-L-proline
-
-
(4S,5R)-4-(benzylcarbamoyl)-1-[(4-tert-butylphenyl)carbonyl]-2-(2-methylpropyl)-5-(1,3-thiazol-2-yl)-L-proline
-
-
(4S,5R)-4-(ethylcarbamoyl)-2-(2-methylpropyl)-5-thiophen-2-yl-1-[[4-(trifluoromethyl)phenyl]carbonyl]-L-proline
-
-
(4S,5R)-4-(methylcarbamoyl)-2-(2-methylpropyl)-5-thiophen-2-yl-1-[[4-(trifluoromethyl)phenyl]carbonyl]-L-proline
-
-
(4S,5R)-4-carbamoyl-2-(2-methylpropyl)-5-(1,3-thiazol-2-yl)-1-[[4-(trifluoromethyl)phenyl]carbonyl]-L-proline
-
-
(4S,5R)-4-carbamoyl-2-(2-methylpropyl)-5-thiophen-2-yl-1-[[4-(trifluoromethyl)phenyl]carbonyl]-L-proline
-
-
(4S,5R)-4-[(1-methylethyl)carbamoyl]-2-(2-methylpropyl)-5-thiophen-2-yl-1-[[4-(trifluoromethyl)phenyl]carbonyl]-L-proline
-
-
(4S,5R)-4-[(methoxysulfinyl)carbamoyl]-2-(2-methylpropyl)-5-(1,3-thiazol-2-yl)-1-[[4-(trifluoromethyl)phenyl]carbonyl]-L-proline
-
-
(4S,5R)-4-[(methoxysulfinyl)carbamoyl]-2-(2-methylpropyl)-5-thiophen-2-yl-1-[[4-(trifluoromethyl)phenyl]carbonyl]-L-proline
-
-
(4S,5R)-4-[[(benzyloxy)sulfinyl]carbamoyl]-1-[(4-tert-butylphenyl)carbonyl]-2-(2-methylpropyl)-5-(1,3-thiazol-2-yl)-L-proline
-
-
(5,7-difluoro-1-propyl-2,3,4,9-tetrahydro-1H-carbazol-1-yl)acetic acid
-
-
(5,8-dicyano-1-propyl-2,3,4,9-tetrahydro-1H-carbazol-1-yl)acetic acid
-
-
(5-cyano-6-fluoro-8-methyl-1-propyl-3,4-dihydro-1H-[1]benzothieno[2,3-c]pyran-1-yl)acetic acid
-
-
(5-cyano-8-fluoro-1-propyl-2,3,4,9-tetrahydro-1H-carbazol-1-yl)acetic acid
-
-
(5-cyano-8-methyl-1-propyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetic acid
-
-
(5-cyano-8-methyl-1-propyl-2,3,4,9-tetrahydro-1H-carbazol-1-yl)acetic acid
-
-
(5R)-1-[(4-tert-butyl-3-methoxyphenyl)carbonyl]-4-(methoxymethyl)-2-(2-methylpropyl)-5-(1,3-thiazol-2-yl)-L-proline
-
-
(5S)-5-tert-butyl-3-(1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-1-(3-methylbutyl)-1,5-dihydro-2H-pyrrol-2-one
-
-
(6R,7R,8S,9R)-4-bromo-7,8-dihydroxy-7,8,9,10-tetrahydro-5H,6H-6,9-epoxy-1,2,5a,10a-tetraazacycloocta[1,2,3-cd]inden-5-one
-
-
(NH4)2SO4
-
above 60 mM
([[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]oxy]methyl)phosphonic acid
-
-
1,3-bis-(4-chloro-1H(3H)-triazolo[4,5-g]quinoline)propan-2-one
-
moderate antiproliferative activity for the cell lines tested
1,3-dimethyl-N-[4-(pyrrolidin-1-ylsulfonyl)phenyl]-1H-pyrazole-5-carboxamide
-
-
1-(1-methylethyl)-N-[4-[(2-methylpiperidin-1-yl)sulfonyl]phenyl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide
-
-
1-(2,5-difluorophenyl)-3-(2,5-difluorophenyl)triazene
1-(2,5-difluorophenyl)-3-(3'-trifluoromethylphenyl)triazene
1-(2,5-difluorophenyl)-3-phenyltriazene
1-(2,5-difluorophenyl)azopyrrolidine
1-(2-cyclopropylethyl)-3-(1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-6-fluoro-4-hydroxyquinolin-2(1H)-one
-
-
1-(3,4-dichlorophenyl)azopyrrolidine
1-(3-bromophenyl)azopiperidine
1-(3-bromophenyl)azopyrrolidine
1-(3-chloro)-3-phenyltriazene N-methyl
1-(3-chlorophenyl)azopiperidine
1-(3-chlorophenyl)azopyrrolidine
1-(3-nitrophenyl)-3-(3'-nitrophenyl)triazene
1-(3-nitrophenyl)-3-methyl-3-phenyltriazene
1-(3-nitrophenyl)-3-phenyltriazene
1-(3-nitrophenyl)azopiperidine
1-(3-nitrophenyl)azopyrrolidine
1-(3-trifluoromethylphenyl)azopyrrolidine
1-(4-bromophenyl)azopiperidine
1-(4-bromophenyl)azopyrrolidine
1-(4-chlorophenyl)azopiperidine
1-(4-chlorophenyl)azopyrrolidine
1-(4-methoxyphenyl)azopyrrolidine
1-(4-methylphenyl)-3-methyl-3-phenyltriazene
1-(4-nitrophenyl)azopyrrolidine
1-(cyclobutylamino)-3-(1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-4-hydroxyquinolin-2(1H)-one
-
-
1-benzyl-N-(2,3-dimethylphenyl)-3,5-dimethyl-1H-pyrazole-4-carboxamide
NIC04, in combination with NIC02, i.e. N-(3-cyano-5,6-dihydro-4H-cyclopenta[b]thiophen-2-yl)-4-methyl-2-phenyl-1,3-thiazole-5-carboximidic acid
1-benzyl-N-[4-[(2-methylpiperidin-1-yl)sulfonyl]phenyl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide
-
-
1-cyclohexyl-2-(2-fluoro-4-[[2-(3-oxomorpholin-4-yl)-5-(2-oxopyrrolidin-1-yl)benzyl]oxy]phenyl)-1H-benzimidazole-5-carboxylic acid
-
-
1-cyclohexyl-2-(2-fluoro-4-[[2-(4-hydroxypiperidin-1-yl)-5-(2-oxopyrrolidin-1-yl)benzyl]oxy]phenyl)-1H-benzimidazole-5-carboxylic acid
-
-
1-cyclohexyl-2-(2-fluoro-4-[[2-(4-methylpiperazin-1-yl)-5-(2-oxopyrrolidin-1-yl)benzyl]oxy]phenyl)-1H-benzimidazole-5-carboxylic acid
-
-
1-cyclohexyl-2-(2-fluoro-4-[[2-methoxy-5-(2-oxopyrrolidin-1-yl)benzyl]oxy]phenyl)-1H-benzimidazole-5-carboxylic acid
-
-
1-cyclohexyl-2-(2-fluoro-4-[[2-morpholin-4-yl-5-(2-oxopiperidin-1-yl)benzyl]oxy]phenyl)-1H-benzimidazole-5-carboxylic acid
-
-
1-cyclohexyl-2-(2-fluoro-4-[[2-morpholin-4-yl-5-(2-oxopyrrolidin-1-yl)benzyl]oxy]phenyl)-1H-benzimidazole-5-carboxylic acid
-
-
1-cyclohexyl-2-(2-fluoro-4-[[5-(2-oxopyrrolidin-1-yl)-2-piperidin-1-ylbenzyl]oxy]phenyl)-1H-benzimidazole-5-carboxylic acid
-
-
1-cyclohexyl-2-(3-furyl)-1H-benzimidazole-5-carboxylic acid
-
-
1-cyclohexyl-2-(4-[[2-morpholin-4-yl-5-(2-oxopyrrolidin-1-yl)benzyl]oxy]phenyl)-1H-indole-5-carboxylic acid
-
-
1-cyclohexyl-2-(4-[[4-(dimethylcarbamoyl)phenyl](phenyl)methoxy]-2-fluorophenyl)-1H-benzimidazole-5-carboxylic acid
-
-
1-cyclohexyl-2-(4-[[5-(1,1-dioxidoisothiazolidin-2-yl)-2-morpholin-4-ylbenzyl]oxy]-2-fluorophenyl)-1H-benzimidazole-5-carboxylic acid
-
-
1-cyclohexyl-2-(4-[[5-(dimethylcarbamoyl)-2-morpholin-4-ylbenzyl]oxy]-2-fluorophenyl)-1H-benzimidazole-5-carboxylic acid
-
-
1-cyclohexyl-2-furan-3-yl-N-[(1S)-2-(5-hydroxy-1H-indol-3-yl)-1-(1,3-thiazol-4-yl)ethyl]-1H-benzimidazole-5-carboxamide
-
-
1-cyclohexyl-2-phenyl-1H-benzimidazole-5-carboxylic acid
-
-
1-cyclohexyl-2-phenyl-1H-indole-5-carboxylic acid
-
-
1-cyclohexyl-2-[2-fluoro-4-([5-[(1-methylethyl)carbamoyl]-2-morpholin-4-ylbenzyl]oxy)phenyl]-1H-benzimidazole-5-carboxylic acid
-
-
1-cyclohexyl-2-[2-fluoro-4-([5-[(methoxyacetyl)(methyl)amino]-2-morpholin-4-ylbenzyl]oxy)phenyl]-1H-benzimidazole-5-carboxylic acid
-
-
1-cyclohexyl-2-[2-fluoro-4-[(2-morpholin-4-ylbenzyl)oxy]phenyl]-1H-benzimidazole-5-carboxylic acid
-
-
1-cyclohexyl-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-pyridin-2-yl-1H-benzimidazole-5-carboxamide
-
-
1-ethyl-N-[4-[(2-methylpiperidin-1-yl)sulfonyl]phenyl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide
-
-
1-methyl-3-(trifluoromethyl)-N-[4-(pyrrolidinylsulfonyl)-phenyl]-1H-pyrazole-5-carboxamide
-
specific inhibitor, inhibits RdRp complex activity
1-methyl-3-(trifluoromethyl)-N-[4-(pyrrolidinylsulfonyl)phenyl]-1H-pyrazole-5-carboxamide
-
-
1-methyl-3-(trifluoromethyl)-N-[4-pyrrolidinylsulfonylphenyl]-1H-pyrazole-5-carboxamide
-
-
1-methyl-4-(2,5-difluorophenylazo)piperazine
1-methyl-4-(phenylazo)piperazine
1-methyl-4-(trifluoromethyl)-N-(4-[[4-(trifluoromethyl)piperidin-1-yl]sulfonyl]phenyl)-1H-pyrrole-2-carboxamide
-
-
1-methyl-5-[[4-(pyrrolidin-1-ylsulfonyl)phenoxy]methyl]-3-(trifluoromethyl)-1H-pyrazole
-
-
1-methyl-N-[4-(morpholin-4-ylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide
-
-
1-methyl-N-[4-(morpholin-4-ylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-pyrrole-2-carboxamide
-
-
1-methyl-N-[4-(piperazin-1-ylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide
-
-
1-methyl-N-[4-(piperazin-1-ylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-pyrrole-2-carboxamide
-
-
1-methyl-N-[4-(piperidin-1-ylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide
-
-
1-methyl-N-[4-(piperidin-1-ylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-pyrrole-2-carboxamide
-
-
1-methyl-N-[4-(pyrrolidin-1-ylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide
-
first-in-class nonnucleoside inhibitor of RNA-dependent RNA polymerase complex activity, highly active against multiple primary isolates of diverse measles virus genotypes circulating worldwide, high developmental potential as a potent therapeutic against measles virus, active concentrations of 35-145 nM
1-methyl-N-[4-[(2-methylpiperidin-1-yl)sulfonyl]phenyl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide
-
-
1-methyl-N-[4-[(2-methylpiperidin-1-yl)sulfonyl]phenyl]-4-(trifluoromethyl)-1H-pyrrole-2-carboxamide
-
-
1-methyl-N-[4-[(4-methylpiperidin-1-yl)sulfonyl]phenyl]-4-(trifluoromethyl)-1H-pyrrole-2-carboxamide
-
-
1-phenyl-3-(3'-trifluoromethylphenyl)triazene
1-phenyl-3-benzyltriazene
1-phenyl-3-methyl-3-benzyltriazene
1-phenyl-3-phenyltriazene
1-phenyl-azopiperidine
1-phenyl-azopyrrolidine
1-phenyl-N-[4-(pyrrolidin-1-ylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide
-
-
1-phenylazo-4-oxopiperidine
1-[(4-tert-butyl-3-methoxyphenyl)carbonyl]-4-[(2-chlorophenyl)carbamoyl]-2-(1,3-thiazol-4-ylmethyl)piperazine-2-carboxylic acid
-
-
1-[1-(2,5-difluorophenyl)-3-(3-trifluoromethylphenyl)-triazen-3-yl]-N,N-dimethyl-3-propanamine
1-[1-(2,5-difluorophenyl)-3-phenyltriazen-3-yl]-N,N-dimethyl-3-propanamine
1-[1-(2,6-difluorophenyl)-3-phenyltriazen-3-yl]-N,N-dimethyl-3-propanamine
1-[1-(3-nitrophenyl)-3-phenyltriazen-3-yl]-N,N-dimethyl-3-propanamine
1-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]-2-[4-(pyrrolidin-1-ylsulfonyl)phenyl]ethanol
-
-
1-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]-2-[4-(pyrrolidin-1-ylsulfonyl)phenyl]ethanone
-
-
1-[2-(diethylamino)ethyl]-6-(1H-imidazol-1-yl)-1,3-dihydro-2H-benzimidazol-2-one
-
1-[[4-([[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]carbonyl]amino)phenyl]sulfonyl]piperidine-2-carboxylic acid
-
-
1-[[4-([[1-methyl-4-(trifluoromethyl)-1H-pyrrol-2-yl]carbonyl]amino)phenyl]sulfonyl]piperidine-3-carboxylic acid
-
-
1-[[4-([[1-methyl-4-(trifluoromethyl)-1H-pyrrol-2-yl]carbonyl]amino)phenyl]sulfonyl]proline
-
-
12-cyclohexylindolo[1,2-c][1,3]benzoxazine-9-carboxylic acid
-
dihedral angle between the C2-aryl group and the indole ring is 24°
13-cyclohexyl-3-[[2-morpholin-4-yl-5-(2-oxopyrrolidin-1-yl)benzyl]oxy]-6,7-dihydroindolo[1,2-d][1,4]benzoxazepine-10-carboxylic acid
-
-
13-cyclohexyl-5-(2-piperidin-1-ylethyl)-6,7-dihydro-5H-indolo[1,2-d][1,4]benzodiazepine-10-carboxylic acid
-
-
13-cyclohexyl-6,7-dihydro-5H-indolo[1,2-d][1,4]benzodiazepine-10-carboxylic acid
-
dihedral angle between the C2-aryl group and the indole ring is 46°
13-cyclohexyl-6,7-dihydro-5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid
-
dihedral angle between the C2-aryl group and the indole ring is 53°
13-cyclohexyl-6,7-dihydroindolo[1,2-d][1,4]benzothiazepine-10-carboxylate
-
dihedral angle between the C2-aryl group and the indole ring is 56°
13-cyclohexyl-6,7-dihydroindolo[1,2-d][1,4]benzoxazepine-10-carboxylic acid
-
dihedral angle between the C2-aryl group and the indole ring is 43°
14-cyclohexyl-7,8-dihydro-6H-indolo[1,2-e][1,5]benzoxazocine-11-carboxylate
-
dihedral angle between the C2-aryl group and the indole ring is 61°
1H-benzimidazole-5-carboxylic acid, 2-[4-[[4'-chloro-4-(2-oxo-1-pyrrolidinyl)[1,1'-biphenyl]-2-yl]methoxy]-2-fluorophenyl]-1-cyclohexyl hydrochloride
i.e. JTK-109
2',3'-dideoxycytidine triphosphate
-
inhibition is higher in presence of Mn2+ than in presence of Mg2+
2',3'-dideoxyguanosine triphosphate
-
inhibition is higher in presence of Mn2+ than in presence of Mg2+
2'-C-ethynyl-2'-fluoro-uridine triphosphate
-
-
2'-C-ethynyl-4'-fluoro-uridine triphosphate
-
-
2'-C-ethynyl-uridine triphosphate
-
-
2'-C-ethynylcytidine
2'-C-methyl-3'-O-L-valylcytidine
-
-
2'-C-methyl-4'-fluoro-uridine triphosphate
-
-
2'-C-methyl-uridine triphosphate
-
-
2'-C-methyladenosine
-
-
2'-C-methylcytidine
2'-C-methylguanosine
2'-C-propynyl-4'-fluoro-uridine triphosphate
-
-
2'-C-propynyl-uridine triphosphate
-
-
2'-deoxy-2'-fluoro-2'-methylcytidine
-
-
2'-deoxy-2'-fluorocytidine
-
-
2'-deoxycytidine triphosphate
-
inhibition is higher in presence of Mn2+ than in presence of Mg2+
2'-dGTP
-
inhibition is higher in presence of Mn2+ than in presence of Mg2+
2'-fluoro-2'C-methylcytidine-5'-triphosphate
-
acts as a chain terminator after incorporated during RNA synthesis. It is readily incorporated into a growing primer by NS5B but is also efficiently excised
2'-fluoro-2'C-methyluridine-5'-triphosphate
-
acts as a chain terminator after incorporated during RNA synthesis. It is readily incorporated into a growing primer by NS5B but is also efficiently excised. Although 2'C-modified CTP analogs are more efficiently incorporated compared with the UTP analog, the UTP analog is a better inhibitor because of its resistance to ATP-dependent excision
2'-O-methylcytidine
-
-
2'C-methylcytidine triphosphate
-
acts as a chain terminator after incorporated during RNA synthesis. It is readily incorporated into a growing primer by NS5B but is also efficiently excised
2,3-bis(4-fluorophenyl)quinoxaline-6-carboxylic acid
-
2,3-bis(4-methylphenyl)quinoxaline-6-carboxylic acid
-
2,3-di-2-furylquinoxaline-6-carboxylic acid
-
2,3-dimethyl-N-{[(1S,9aR)-9a-methyloctahydro-2H-quinolizin-1-yl]methyl}-4-[(E)-phenyldiazenyl]aniline
2,3-dimethyl-N-{[(1S,9aR)-9a-methyloctahydro-2H-quinolizin-1-yl]methyl}-4-{(E)-[3-(trifluoromethyl)phenyl]diazenyl}aniline
2,3-diphenylquinoxaline-6-carboxylic acid
-
2,4-dioxo-4-phenylbutanoic acid
-
specific inhibitor
2-(2-C-methyl-b-D-ribofuranosyl)-2,6-dihydro-7H-2,3,5,6-tetraazabenzo[cd]azulen-7-one
-
-
2-(3-[[(2-chlorobenzyl)carbamoyl]amino]thiophen-2-yl)-5,6-dihydroxypyrimidine-4-carboxylic acid
-
-
2-(4-benzylphenyl)-3-cyclohexyl-1-methyl-1H-indole-6-carboxylic acid
-
-
2-(4-chlorophenyl)-3-cyclohexyl-1-[2-[4-(diethylamino)piperidin-1-yl]-2-oxoethyl]-1H-indole-6-carboxylic acid
-
-
2-(4-[[2-(4-acetylpiperazin-1-yl)-5-(2-oxopyrrolidin-1-yl)benzyl]oxy]-2-fluorophenyl)-1-cyclohexyl-1H-benzimidazole-5-carboxylic acid
-
-
2-(4-[[2-(4-carboxypiperidin-1-yl)-5-(2-oxopyrrolidin-1-yl)benzyl]oxy]-2-fluorophenyl)-1-cyclohexyl-1H-benzimidazole-5-carboxylic acid
-
-
2-(4-[[2-(4-chlorophenoxy)-5-(2-oxopyrrolidin-1-yl)benzyl]oxy]-2-fluorophenyl)-1-cyclohexyl-1H-benzimidazole-5-carboxylic acid
-
-
2-(4-[[4'-chloro-4-(2-oxopyrrolidin-1-yl)biphenyl-2-yl]methoxy]-2-fluorophenyl)-1-cyclohexyl-1H-benzimidazole-5-carboxylic acid
-
-
2-(4-[[5-(acetylamino)-2-morpholin-4-ylbenzyl]oxy]-2-fluorophenyl)-1-cyclohexyl-1H-benzimidazole-5-carboxylic acid
-
-
2-([3-[1-(2-cyclopropylethyl)-6-fluoro-4-hydroxy-2-oxo-1,2-dihydroquinolin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]oxy)acetamide
-
-
2-([3-[1-(cyclobutylamino)-4-hydroxy-2-oxo-1,2-dihydroquinolin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]oxy)acetamide
A-782759
2-([3-[4-hydroxy-1-(3-methylbutyl)-2-oxo-1,2-dihydro-1,8-naphthyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]oxy)acetamide
-
-
2-([5-(2,4-dichlorophenyl)-1,3,4-thiadiazol-2-yl]imino)-1,3-thiazolidin-4-one
-
-
2-([5-(2,6-dichlorophenyl)-1,3,4-thiadiazol-2-yl]imino)-1,3-thiazolidin-4-one
-
-
2-([5-(2-chloro-6-fluorophenyl)-1,3,4-thiadiazol-2-yl]-imino)-1,3-thiazolidin-4-one
-
-
2-([5-(2-chlorophenyl)-1,3,4-thiadiazol-2-yl]imino)-1,3-thiazolidin-4-one
-
-
2-([5-(2-fluorophenyl)-1,3,4-thiadiazol-2-yl]imino)-1,3-thiazolidin-4-one
-
-
2-([5-(3-fluorophenyl)-1,3,4-thiadiazol-2-yl]imino)-1,3-thiazolidin-4-one
-
-
2-([5-(pyridin-3-yl)-1,3,4-thiadiazol-2-yl]imino)-1,3-thiazolidin-4-one
-
-
2-([[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]carbonyl]amino)-5-(pyrrolidin-1-ylsulfonyl)phenyl 1-methyl-3-(trifluoromethyl)-1H-pyrazole-5-carboxylate
-
-
2-amino-7-(2-C-methyl-beta-D-ribofuranosyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
-
-
2-bromo-5-methoxy-N-[4-(pyrrolidin-1-ylsulfonyl)phenyl]benzamide
-
-
2-chloro-4-nitro-N-[4-(pyrrolidin-1-ylsulfonyl)phenyl]benzamide
-
-
2-cyano-N'-[(1Z)-(3,4,5-trihydroxyphenyl)methylene]acetohydrazide
-
-
2-fluoro-N-[4-(pyrrolidin-1-ylsulfonyl)phenyl]-5-(trifluoromethyl)benzamide
-
-
2-methyl-N-[4-(pyrrolidin-1-ylsulfonyl)phenyl]-6-(trifluoromethyl)pyridine-3-carboxamide
-
-
2-nitro-N-[4-(pyrrolidin-1-ylsulfonyl)phenyl]-4-(trifluoromethyl)benzamide
-
-
2-[2-chloro-4-(2-[2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]ethyl)phenyl]-2-methylpropanenitrile
-
-
2-[4-(2-[(2R)-2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl]ethyl)-2-fluorophenyl]-2-methylpropanenitrile
-
-
2-[4-(2-[2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]ethyl)-2-fluorophenyl]-2-methylpropanenitrile
-
-
2-[4-(benzyloxy)phenyl]-1-cyclopentyl-1H-benzimidazole-5-carboxamide
-
-
2-[4-(benzyloxy)phenyl]-1-cyclopentyl-1H-benzimidazole-5-carboxylic acid
-
-
2-[4-(benzyloxy)phenyl]-3-cyclohexyl-1-[2-(dimethylamino)-2-oxoethyl]-1H-indole-6-carboxylic acid
-
-
2-[4-([4'-chloro-4-[(4-hydroxypiperidin-1-yl)carbonyl]biphenyl-2-yl]methoxy)-2-fluorophenyl]-1-cyclohexyl-1H-benzimidazole-5-carboxylic acid
-
-
2-[4-([5-[acetyl(1-methylethyl)amino]-2-morpholin-4-ylbenzyl]oxy)-2-fluorophenyl]-1-cyclohexyl-1H-benzimidazole-5-carboxylic acid
-
-
2-[4-([5-[acetyl(methyl)amino]-2-morpholin-4-ylbenzyl]oxy)-2-fluorophenyl]-1-cyclohexyl-1H-benzimidazole-5-carboxylic acid
-
-
2-[4-[(5-chloro-2-morpholin-4-ylbenzyl)oxy]-2-fluorophenyl]-1-cyclohexyl-1H-benzimidazole-5-carboxylic acid
-
-
2-[5-[[4-(pyrrolidin-1-ylsulfonyl)phenyl]carbamoyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzoic acid
-
-
3'-azido-3'-deoxythymidine triphosphate
incorporated by SARS-CoV RNA-dependent RNA polymerase (RdRp), and blocks further incorporation by the polymerase
3'-dATP
incorporation of the 3'-deoxynucleotide triphosphate fully prevents extension of a product in the presence of the next correct ribonucleotide
3'-dCTP
incorporation of the 3'-deoxynucleotide triphosphate fully prevents extension of a product in the presence of the next correct ribonucleotide
3'-deoxy-5'-O-([2-[(2,2-dimethyl-1-methylidenepropyl)sulfanyl]ethoxy][2-[(2,2-dimethylpropanoyl)sulfanyl]ethoxy]phosphoryl)cytidine
-
-
3'-deoxycytidine
-
-
3'-dGTP
3'-dUTP
3'-fluoro-3'-deoxythymidine triphosphate
incorporated by SARS-CoV RNA-dependent RNA polymerase (RdRp), and blocks further incorporation by the polymerase
3,4,5-trihydroxybenzaldehyde O-methyloxime
-
-
3-(1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-1-(3-methylbutyl)quinolin-2(1H)-one
-
-
3-(2-C-methyl-b-D-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(3H,8H)-dione
-
-
3-(3-nitrophenylazo)cytisine
3-(4-chlorophenylazo)cytisine
3-(benzyloxy)-13-cyclohexyl-6,7-dihydroindolo[1,2-d][1,4]benzoxazepine-10-carboxylic acid
-
-
3-(isopropyl[(4-methylphenyl)sulfonyl]amino)-5-phenylthiophene-2-carboxylic acid
-
-
3-([(2,4-dimethylphenyl)sulfonyl]amino)-5-phenylthiophene-2-carboxylic acid
-
-
3-([(4-chloro-2,5-dimethylphenyl)sulfonyl]amino)-5-phenylthiophene-2-carboxamide
-
-
3-allyl-5,8-dichloro-1,2,3,4-tetrahydrocyclopenta[b]indole-3-carboxylic acid
-
-
3-allyl-8-cyano-5-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indole-3-carboxylic acid
-
-
3-allyl-8-cyano-5-methyl-1,2,3,4-tetrahydrocyclopenta[b]indole-3-carboxylic acid
-
-
3-allyl-8-cyano-7-fluoro-5-methyl-1,2,3,4-tetrahydrocyclopenta[b]indole-3-carboxylic acid
-
-
3-benzyl-5-chloropyrido[3,2-g]quinoxalin-2(1H)-one
-
moderate antiproliferative activity for the cell lines tested
3-butyl-5,8-dichloro-1,2,3,4-tetrahydrocyclopenta[b]indole-3-carboxylic acid
-
-
3-butyl-8-cyano-5-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indole-3-carboxylic acid
-
-
3-butyl-8-cyano-5-methyl-1,2,3,4-tetrahydrocyclopenta[b]indole-3-carboxylic acid
-
-
3-butyl-8-cyano-7-fluoro-5-methyl-1,2,3,4-tetrahydrocyclopenta[b]indole-3-carboxylic acid
-
-
3-cyclohexyl-1-(2-oxo-2-piperidin-1-ylethyl)-2-phenyl-1H-indole-6-carboxylic acid
-
-
3-cyclohexyl-1-(2-[methyl[(1-methylpiperidin-3-yl)methyl]amino]-2-oxoethyl)-2-phenyl-1H-indole-6-carboxylic acid
-
-
3-cyclohexyl-1-methyl-2-(4-[[2-morpholin-4-yl-5-(2-oxopyrrolidin-1-yl)benzyl]oxy]phenyl)-1H-indole-6-carboxylic acid
-
-
3-cyclohexyl-1-[2-(dimethylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-1H-indole-6-carboxylic acid
-
-
3-cyclohexyl-1-[2-(dimethylamino)-2-oxoethyl]-2-phenyl-1H-indole-6-carboxylic acid
-
-
3-cyclohexyl-1-[2-(dimethylamino)-2-oxoethyl]-2-phenyl-1H-pyrrolo[2,3-b]pyridine-6-carboxylic acid
-
-
3-cyclohexyl-2-(3-furyl)-1-methyl-1H-indole-6-carboxylic acid
-
-
3-cyclohexyl-2-(3-furyl)-1H-indole-6-carboxylic acid
-
-
3-cyclohexyl-2-furan-3-yl-1-[2-oxo-2-(4-pyrrolidin-1-ylpiperidin-1-yl)ethyl]-1H-indole-6-carboxylic acid
-
-
3-cyclohexyl-2-furan-3-yl-N-[(1S)-2-(5-hydroxy-1H-indol-3-yl)-1-(1,3-thiazol-4-yl)ethyl]-1-methyl-1H-indole-6-carboxamide
-
-
3-cyclohexyl-2-phenyl-1H-indole-6-carboxylic acid
-
-
3-cyclohexyl-2-phenyl-1H-pyrrolo[2,3-b]pyridine-6-carboxylic acid
-
-
3-cyclohexyl-2-phenyl-1H-pyrrolo[3,2-b]pyridine-6-carboxylic acid
-
-
3-cyclohexyl-2-phenyl-3H-thieno[2,3-d]imidazole-5-carboxylic acid
-
-
3-cyclohexyl-2-phenylquinoline-6-carboxylic acid
-
-
3-oxo-3-[(2Z)-2-(3,4,5-trihydroxybenzylidene)hydrazino]propanoic acid
-
-
3-tert-butyl-1-methyl-N-[4-(pyrrolidin-1-ylsulfonyl)phenyl]-1H-pyrazole-5-carboxamide
-
-
3-[(1S,9aR)-octahydro-2H-quinolizin-1-ylmethyl]-1-phenyl-3-(trifluoromethylphenyl)triazene
3-[(4-amino-2-tert-butyl-5-methylphenyl)sulfanyl]-6-cyclopentyl-4-hydroxy-6-[2-(4-hydroxyphenyl)ethyl]-5,6-dihydro-2H-pyran-2-one
-
-
3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-5-phenylthiophene-2-carboxylic acid
-
-
3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylpiperidin-4-yl)amino]-5-phenylthiophene-2-carboxylic acid
-
-
3-[[4'-chloro-4-(2-oxopyrrolidin-1-yl)biphenyl-2-yl]methoxy]-13-cyclohexyl-6,7-dihydroindolo[1,2-d][1,4]benzoxazepine-10-carboxylic acid
-
-
4'-azido-cytidine triphosphate
-
acts as a chain terminator after incorporated during RNA synthesis. It is readily incorporated into a growing primer by NS5B but is also efficiently excised
4'-azido-D-arabinofuranosylcytosine
-
-
4'-azidocytidine
4'-C-azidocytidine-5'-triphosphate
causes only partial chain termination
4-(2-C-methyl-b-D-ribofuranosyl)-3-oxo-3,4-dihydropyrazine-2-carboxamide
-
-
4-(chloromethyl)-N-[4-(pyrrolidin-1-ylsulfonyl)phenyl]benzamide
-
-
4-amino-2-chloro-N-[4-(pyrrolidin-1-ylsulfonyl)phenyl]benzamide
-
-
4-bromo-1-methyl-N-[4-(pyrrolidin-1-ylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide
-
-
4-bromo-N-[4-(pyrrolidin-1-ylsulfonyl)phenyl]benzamide
-
-
4-chloro-2-(4-nitrophenyl)-3H-imidazo[4,5-g]quinoline
4-fluoro-N-[4-(pyrrolidin-1-ylsulfonyl)phenyl]benzamide
-
-
4-methyl-N-((5Z)-5-[(5-methyl-2-furyl)methylene]-4-oxo-4,5-dihydro-1,3-thiazol-2-yl)benzenesulfonamide
-
-
4-phenylazo-1-(phenyl)piperazine
4-phenylazo-1-(pyrimidin-2'-yl)piperazine
4-[(E)-(2,4-difluorophenyl)diazenyl]-N-[[(1S,9aR)-9a-methyloctahydro-2H-quinolizin-1-yl]methyl]-5,6,7,8-tetrahydronaphthalen-1-amine}
4-[(E)-(2,5-difluorophenyl)diazenyl]-N-[[(1S,9aR)-9a-methyloctahydro-2H-quinolizin-1-yl]methyl]-5,6,7,8-tetrahydronaphthalen-1-amine}
5'-formylpyrogallol
-
-
5'-O-([2-[(2,2-dimethyl-1-methylidenepropyl)sulfanyl]ethoxy][2-[(2,2-dimethylpropanoyl)sulfanyl]ethoxy]phosphoryl)-2'-O-methylcytidine
-
-
5,6-dihydroxy-2-(1,3-thiazol-5-yl)pyrimidine-4-carboxylic acid
-
-
5,6-dihydroxy-2-(2-thienyl)pyrimidine-4-carboxylic acid
-
-
5,6-dihydroxy-2-phenylpyrimidine-4-carboxylic acid
-
-
5,6-dihydroxy-2-[4-(([(1-naphthylsulfonyl)amino]carbonyl)amino)-3-thienyl]pyrimidine-4-carboxylic acid
-
-
5,8-dichloro-1-propyl-2,3,4,9-tetrahydro-1H-carbazole-1-carboxylic acid
-
-
5,8-dichloro-3-propyl-1,2,3,4-tetrahydrocyclopenta[b]indole-3-carboxylic acid
-
-
5-((Z)-[(4-methylpiperazin-1-yl)imino]methyl)benzene-1,2,3-triol
-
-
5-(2,6-dichlorobenzylidene)-2-[[5-(2,4-dichlorophenyl)-1,3,4-thiadiazol-2-yl]imino]-1,3-thiazolidin-4-one
-
-
5-(2,6-dichlorobenzylidene)-2-[[5-(2,6-dichlorophenyl)-1,3,4-thiadiazol-2-yl]imino]-1,3-thiazolidin-4-one
-
-
5-(2,6-dichlorobenzylidene)-2-[[5-(2-chloro-6-fluorophenyl)-1,3,4-thiadiazol-2-yl]imino]-1,3-thiazolidin-4-one
-
-
5-(2,6-dichlorobenzylidene)-2-[[5-(2-chlorophenyl)-1,3,4-thiadiazol-2-yl]imino]-1,3-thiazolidin-4-one
-
-
5-(2,6-dichlorobenzylidene)-2-[[5-(2-fluorophenyl)-1,3,4-thiadiazol-2-yl]imino]-1,3-thiazolidin-4-one
-
-
5-(2,6-dichlorobenzylidene)-2-[[5-(3-fluorophenyl)-1,3,4-thiadiazol-2-yl]imino]-1,3-thiazolidin-4-one
-
-
5-(2,6-dichlorobenzylidene)-2-[[5-(pyridin-3-yl)-1,3,4-thiadiazol-2-yl]imino]-1,3-thiazolidin-4-one
-
-
5-(2-amino-2-oxoethoxy)-N-[[2,3-bis(4-fluorophenyl)quinoxalin-6-yl]carbonyl]-L-tryptophan
-
5-(3-fluorobenzylidene)-2-[[5-(2,4-dichlorophenyl)-1,3,4-thiadiazol-2-yl]imino]-1,3-thiazolidin-4-one
-
-
5-(3-fluorobenzylidene)-2-[[5-(2,6-dichlorophenyl)-1,3,4-thiadiazol-2-yl]imino]-1,3-thiazolidin-4-one
-
-
5-(3-fluorobenzylidene)-2-[[5-(2-chloro-6-fluorophenyl)-1,3,4-thiadiazol-2-yl]imino]-1,3-thiazolidin-4-one
-
-
5-(3-fluorobenzylidene)-2-[[5-(2-chlorophenyl)-1,3,4-thiadiazol-2-yl]imino]-1,3-thiazolidin-4-one
-
-
5-(3-fluorobenzylidene)-2-[[5-(2-fluorophenyl)-1,3,4-thiadiazol-2-yl]imino]-1,3-thiazolidin-4-one
-
-
5-(3-fluorobenzylidene)-2-[[5-(3-fluorophenyl)-1,3,4-thiadiazol-2-yl]imino]-1,3-thiazolidin-4-one
-
-
5-(3-fluorobenzylidene)-2-[[5-(pyridin-3-yl)-1,3,4-thiadiazol-2-yl]imino]-1,3-thiazolidin-4-one
-
-
5-(4-bromophenylmethylene)-3-(benzenesulfonylamino)-4-oxo-2-thionothiazolidine
-
reversible and non-competitive with nucleotides. Inhibitor appear to form a reversible covalent bond with the NS5B cysteine 366
5-(4-chlorophenylmethylene)-3-(benzenesulfonylamino)-4-oxo-2-thionothiazolidine
-
reversible and non-competitive with nucleotides. Inhibitor appear to form a reversible covalent bond with the NS5B cysteine 366
5-(4-cyanophenyl)-3-([(2-methylphenyl)sulfonyl]amino)thiophene-2-carboxylic acid
-
-
5-(4-[[(2-cyclohexyl-3-phenylquinoxalin-6-yl)carbonyl]amino]phenyl)furan-2-carboxylic acid
-
5-(4-[[(3-cyclohexyl-2-phenylquinoxalin-6-yl)carbonyl]amino]phenyl)furan-2-carboxylic acid
-
5-(carboxymethoxy)-N-[(1-cyclohexyl-2-furan-3-yl-1H-benzimidazol-5-yl)carbonyl]-L-tryptophan
-
-
5-([3,5-bis(trifluoromethyl)phenyl]amino)-3-hydroxyisothiazole-4-carbonitrile
-
-
5-azidomethyl-3-hydroxy-4-hydroxymethyl-pyridine-2-carboxylic acid hydroxyamide
-
i.e. DMB213. Competitive with natural nucleoside triphosphate substrates
5-chloro-3-phenylpyrido[3,2-g]quinoxalin-2(1H)-one
-
compound is equally cytotoxic for all cell lines tested
5-cyano-8-fluoro-1-propyl-2,3,4,9-tetrahydro-1H-carbazole-1-carboxylic acid
-
-
5-cyano-8-methyl-1-propyl-2,3,4,9-tetrahydro-1H-carbazole-1-carboxylic acid
-
-
5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl)amino]-N-methyl-1-benzofuran-3-carboxamide
-
-
5-ethyl-1-(2-C-methyl-b-D-ribofuranosyl)-1,5-dihydro-1,4,5,6,8-pentaazaacenaphthylen-3-amine
-
-
5-fluoro-7-(2-C-methyl-beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
-
-
5-fluorouridine triphosphate
-
5-fluorouridine triphosphate is a strong competitive inhibitor of VPg uridylylation by FMDV 3D in vitro, versus UTP, FUTP, dTTP, ATP, CTP, or GTP, uridylylation at VPg Tyr3, which is located near the active site of 3D, at the RNA binding cleft of 3D, binding structure from crystal structure, overview. No inhibition with oligoT primers
5-hydroxy-N-[[3-(3-methoxyphenyl)-2-(4-methoxyphenyl)quinoxalin-6-yl]carbonyl]-L-tryptophan
-
5-phenyl-2H-1,2,3-triazole-4-carboxylic acid
-
5-[(3,5-dichlorophenyl)amino]-3-hydroxyisothiazole-4-carbonitrile
-
-
5-[(4-bromophenyl)methyl]-2-phenyl-5H-imidazo[4,5-c]pyridine
-
5-[(Z)-(morpholin-4-ylimino)methyl]benzene-1,2,3-triol
-
-
5-[(Z)-(phenylimino)methyl]benzene-1,2,3-triol
-
-
5-[[(4-chlorophenyl)sulfonyl]amino]-2-methyl-1-benzofuran-3-carboxylic acid
Q6DLV0
crystallization data, the inhibitor binds to the protein as a dimer and causes conformational changes in the protein
5BSL3.2N
-
the complementary strand of 5BSL3.2 inhibits the enzyme, the bulge structure is indispensable for enzyme binding
-
6-(2-amino-2-oxoethoxy)-N-[[2,3-bis(4-fluorophenyl)quinoxalin-6-yl]carbonyl]-L-tryptophan
-
6-azauridine
6-cyclohexyl-4-methyl-5-(4-[[2-morpholin-4-yl-5-(2-oxopyrrolidin-1-yl)benzyl]oxy]phenyl)-4H-thieno[3,2-b]pyrrole-2-carboxylic acid
-
-
6-cyclohexyl-4-[2-(dimethylamino)-2-oxoethyl]-5-phenyl-4H-thieno[3,2-b]pyrrole-2-carboxylic acid
-
-
6-cyclohexyl-5-phenyl-4H-thieno[3,2-b]pyrrole-2-carboxylic acid
-
-
6-ethoxy-9-(2-C-methyl-b-D-ribofuranosyl)-9H-purine
-
-
6-furan-3-yl-9-b-D-ribofuranosyl-9H-purine
-
-
6-methoxy-9-(2-C-methyl-b-D-ribofuranosyl)-9H-purine
-
-
6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]-5,6-dihydro-2H-pyran-2-one
-
-
6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)sulfanyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one
-
AG-021541
6-[2-(methoxysulfinyl)hydrazino]-9-(2-C-methyl-b-D-ribofuranosyl)-9H-purine
-
-
7-(2-C-methyl-b-D-ribofuranosyl)-5-nitro-7H-pyrrolo[2,3-d]pyrimidin-4-amine
-
-
7-(2-C-methyl-beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
-
-
8,8'-[carbonylbis(imino-3,1-phenylene carbonylimino)]bis(1,3,5-naphthalene-trisulfonic acid)
i.e. NF023
8,8'-[carbonylbis(iminobenzene-3,1-diylcarbonylimino)]dinaphthalene-1,3,5-trisulfonic acid
8-chloro-1-propyl-5-(trifluoromethyl)-2,3,4,9-tetrahydro-1H-carbazole-1-carboxylic acid
-
-
8-cyano-5-fluoro-3-propyl-1,2,3,4-tetrahydrocyclopenta[b]indole-3-carboxylic acid
-
-
8-cyano-5-methyl-3-propyl-1,2,3,4-tetrahydrocyclopenta[b]indole-3-carboxylic acid
-
-
8-cyano-7-fluoro-5-methyl-3-propyl-1,2,3,4-tetrahydrocyclopenta[b]indole-3-carboxylic acid
-
-
9-(5,6-dideoxy-2-C-methyl-6-phosphono-b-D-ribo-hexofuranosyl)-9H-purin-6-amine
-
-
9-(5,6-dideoxy-6-phosphono-b-D-ribo-hexofuranosyl)-9H-purin-6-amine
-
-
9-(5-O-[bis[2-(acetylsulfanyl)ethoxy]phosphoryl]-2-C-methyl-b-D-ribofuranosyl)-6-ethoxy-9H-purine
-
-
A-782759
-
-
A-837093
-
-
acycloguanosine
afzelin
strong binding affinity to the enzyme (RdRp)
alpha-Amanitin
-
alpha-amanitin inhibits extension of B2 RNA by Pol II in vitro
anthranilic acid
-
aptamer F38
-
identification and characterization of aptamers to the 3Dpol enzyme (serotype C). Three of these RNA molecules display inhibitory activity in an in vitro UTP incorporation assay
-
aptamer F47
-
identification and characterization of aptamers to the 3Dpol enzyme (serotype C). Three of these RNA molecules display inhibitory activity in an in vitro UTP incorporation assay
-
aptamer F52
-
identification and characterization of aptamers to the 3Dpol enzyme (serotype C). Three of these RNA molecules display inhibitory activity in an in vitro UTP incorporation assay
-
Astragalin
strong binding affinity to the enzyme (RdRp)
aurintricarboxylic acid
benzimidazole
-
benzyl 1-[[4-([[1-methyl-4-(trifluoromethyl)-1H-pyrrol-2-yl]carbonyl]amino)phenyl]sulfonyl]prolinate
-
-
beta-D-2'-alpha-deoxy-2'-beta-fluoro-2'-C-methyluridine-5'-triphosphate
beta-D-2'-beta-C-ethynyl-7-deaza-adenosine-5'-triphosphate
causes chain termination after incorporation into nascent RNA
beta-D-2'-beta-C-ethynyluridine-5'-triphosphate
beta-D-2'-beta-C-methyladenosine-5'-triphosphate
causes chain termination after incorporation into nascent RNA
beta-D-2'-beta-C-methylcytidine-5'-triphosphate
causes chain termination after incorporation into nascent RNA
beta-D-2'-beta-C-methylguanosine-5'-triphosphate
causes chain termination after incorporation into nascent RNA
beta-D-2'-beta-C-methyluridine-5'-triphosphate
beta-D-2'-deoxy-2'-alpha-fluoro-2'-beta-C-methylcytidine-5'-triphosphate
causes chain termination after incorporation into nascent RNA
beta-D-2'-deoxy-2'-alpha-fluoro-2'-beta-C-methylguanosine-5'-triphosphate
causes chain termination after incorporation into nascent RNA
beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine
i.e. PSI-6130, a selective inhibitor of hepatitis C virus replication that targets the NS5B polymerase
beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine 5'-triphosphate
-
PSI-6130-TP, potent inhibitor
beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine 5'-triphosphate
-
also named RO2433-TP or PSI-6206, potent inhibitor
biorobin
strong binding affinity to the enzyme (RdRp)
conivaptan
binds to RNA-dependent RNA polymerase with high affinity
cyclohexyl 4-([[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]carbonyl]amino)benzenesulfonate
-
-
cyclopropylindolobenzazepine inhibitors
-
cyclosporine A
inhibits HCV replication
dATP
-
IC50 above 0.5 mM
dCTP
-
IC50: 0.04 mM
ddATP
-
IC50 above 1 mM
ddCTP
-
IC50 above 1 mM
ddGTP
-
IC50: above 0.2 mM
ddTTP
-
IC50 above 0.5 mM
delvomycin
-
the protein synthetic activity of the EF-Tu in the replicase complex is eliminated but the Qbeta RNA replicase activity is only slightly affected
dGTP
-
IC50: 0.1 mM
dihydropyranone inhibitor
binding of non-nucleoside inhibitors induces significant fluctuations at the atomic level which are critical for enzymatic activity, with minimalglobal structural alterations. Residue-wise mapping of interactions of non-nucleoside inhibitors at different sites exhibits some conserved interaction patterns of key amino acids and water molecules
dimethyl (2S,4S,5R)-2-(2-methylpropyl)-5-thiophen-2-yl-1-[[4-(trifluoromethyl)phenyl]carbonyl]pyrrolidine-2,4-dicarboxylate
-
-
dTTP
-
IC50 above 0.5 mM
eltrombopag
binds to RNA-dependent RNA polymerase with high affinity
ErbB3-binding protein 1
-
specifically interacts with the catalytic subunit PB1 of influenza virus RNA polymerase near the catalytic site for RNA polymerization
-
ergotamine
binds to RNA-dependent RNA polymerase with high affinity
ethyl (2E)-3-[4-([[1-([[2,3-bis(4-fluorophenyl)quinoxalin-6-yl]carbonyl]amino)cyclobutyl]carbonyl]amino)phenyl]prop-2-enoate
-
ethyl (2E)-3-[4-([[1-([[2,3-bis(4-fluorophenyl)quinoxalin-6-yl]carbonyl]amino)cyclopentyl]carbonyl]amino)phenyl]prop-2-enoate
-
ethyl (2E)-3-[4-([[2,3-bis(4-fluorophenyl)quinoxalin-6-yl]carbonyl]amino)phenyl]prop-2-enoate
-
ethyl 2-methylimidazo[1,2-a]pyrrolo[2,3-c]pyridin-8-carboxylate
AG110, potent inhibitor of pestivirus replication, does not inhibit the in vitro activity of recombinant bovine viral diarrhea virus RdRp but inhibits the activity of bovine viral diarrhea virus replication complexes
Ethyl 4-(phenylazo)-piperazincarboxylate
favipiravir
filibuvir
-
-
fisetin
high affinities with the RNA-polymerase active site
Fructus Ligustri Lucidi aqueous extract
-
0.005 mg/ml, inhibits intracellular NS5B-catalyzed RNA synthesis
-
galidesivir
GDP
-
competitive with GTP
gliotoxin
GS-9669
-
-
guanidine
-
blocks the initiation step of RNA synthesis in vitro
HA1077
-
i.e. fasudil, reduces the levels of intracellular viral RNA by 70% at 0.02 mM, the RdRp activity of HCV NS5B is not inhibited by the PRK2 inhibitor, but its activation by phosphorylation through PRK2
heparin
HgCl2
-
inhibition is reversed by incubation with an excess amount of dithiothreitol and 2-mercaptoethanol
IDX-184
high potential to fight the SARS-CoV-2 strain specifically
imidazole
tolerable at low concentrations, but inhibits at concentrations higher than 25 mM
indole diamide inhibitors
-
indole-N-acetamide inhibitors
-
indolo-benzoxazocine inhibitors
-
Isoquinoline
-
JTK-109
-
potent inhibitor
K+
-
above 10 mM
kaempferol
strong binding affinity to the enzyme (RdRp)
lomibuvir
-
-
methyl 1-[[4-([[1-methyl-4-(trifluoromethyl)-1H-pyrrol-2-yl]carbonyl]amino)phenyl]sulfonyl]piperidine-2-carboxylate
-
-
methyl 2-[5-[[4-(pyrrolidin-1-ylsulfonyl)phenyl]carbamoyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzoate
-
-
methyl 5-(2-amino-2-oxoethoxy)-N-[[2,3-bis(4-fluorophenyl)quinoxalin-6-yl]carbonyl]-L-tryptophanate
-
methyl 6-(2-amino-2-oxoethoxy)-N-[[2,3-bis(4-fluorophenyl)quinoxalin-6-yl]carbonyl]-L-tryptophanate
-
methyl N-[(2,3-difuran-2-ylquinoxalin-6-yl)carbonyl]-5-hydroxy-L-tryptophanate
-
methyl N-[(2,3-diphenylquinoxalin-6-yl)carbonyl]-5-hydroxy-L-tryptophanate
-
methyl N-[(2,3-diphenylquinoxalin-6-yl)carbonyl]-6-hydroxy-L-tryptophanate
-
methyl N-[(2,3-diphenylquinoxalin-6-yl)carbonyl]-L-tryptophanate
-
methyl N-[(2,3-dipyridin-2-ylquinoxalin-6-yl)carbonyl]-L-tryptophanate
-
methyl N-[(2,3-ditetrahydrofuran-2-ylquinoxalin-6-yl)carbonyl]-6-hydroxy-L-tryptophanate
-
methyl N-[(2,3-ditetrahydrofuran-2-ylquinoxalin-6-yl)carbonyl]-L-tryptophanate
-
methyl N-[[2,3-bis(3-methoxyphenyl)quinoxalin-6-yl]carbonyl]-6-hydroxy-L-tryptophanate
-
methyl N-[[2,3-bis(3-methoxyphenyl)quinoxalin-6-yl]carbonyl]-L-tryptophanate
-
methyl N-[[2,3-bis(4-fluorophenyl)quinoxalin-6-yl]carbonyl]-5-(2-methoxy-2-oxoethoxy)-L-tryptophanate
-
methyl N-[[2,3-bis(4-fluorophenyl)quinoxalin-6-yl]carbonyl]-5-hydroxy-L-tryptophanate
-
methyl N-[[2,3-bis(4-fluorophenyl)quinoxalin-6-yl]carbonyl]-5-[[(2E)-4-methoxy-4-oxobut-2-en-1-yl]oxy]-L-tryptophanate
-
methyl N-[[2,3-bis(4-fluorophenyl)quinoxalin-6-yl]carbonyl]-6-(2-methoxy-2-oxoethoxy)-L-tryptophanate
-
methyl N-[[2,3-bis(4-fluorophenyl)quinoxalin-6-yl]carbonyl]-6-hydroxy-L-tryptophanate
-
methyl N-[[2,3-bis(4-fluorophenyl)quinoxalin-6-yl]carbonyl]-6-[[(2E)-4-methoxy-4-oxobut-2-en-1-yl]oxy]-L-tryptophanate
-
methyl N-[[2,3-bis(4-fluorophenyl)quinoxalin-6-yl]carbonyl]-L-tryptophanate
-
methyl N-[[2,3-bis(4-methylphenyl)quinoxalin-6-yl]carbonyl]-5-hydroxy-L-tryptophanate
-
methyl N-[[2,3-bis(4-methylphenyl)quinoxalin-6-yl]carbonyl]-6-hydroxy-L-tryptophanate
-
methyl N-[[2,3-bis(4-methylphenyl)quinoxalin-6-yl]carbonyl]-L-tryptophanate
-
Mycophenolic acid
Myricitrin
strong binding affinity to the enzyme (RdRp)
N'-[4-(2,5-difluorophenylazo)phenyl]-N,N-dimethylpropane-1,3-diamine
N'-[4-(2,6-difluorophenylazo)phenyl]-N,N-dimethylpropane-1,3-diamine
N,1-dimethyl-N-[4-(piperidin-1-ylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide
-
-
N,N'-[4-(pyrrolidin-1-ylsulfonyl)benzene-1,2-diyl]bis[1-methyl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide]
-
-
N,N-dimethyl-1-(1,3-diphenyltriazen-3-yl)-3-propanamine
N,N-dimethyl-1-[1-(4-nitrophenyl)-3-phenyltriazen-3-yl]-3-propanamine
N,N-dimethyl-1-[1-phenyl-3-(3-trifluoromethylphenyl)triazen-3-yl]-3-propanamine
N,N-dimethyl-1-[3-phenyl-1-(p-tolyl)triazen-3-yl]-3-propanamine
N,N-dimethyl-N'-4-(4'-tolylazo)phenylpropane-1,3-diamine
N,N-dimethyl-N'-[4-(3-nitrophenylazo)phenyl]propane-1,3-diamine
N,N-dimethyl-N'-[4-(4-nitrophenylazo)phenyl]propane-1,3-diamine
N-(3-cyano-5,6-dihydro-4H-cyclopenta[b]thiophen-2-yl)-4-methyl-2-phenyl-1,3-thiazole-5-carboxamide
a non-nucleoside inhibitor
N-(3-cyano-5,6-dihydro-4H-cyclopenta[b]thiophen-2-yl)-4-methyl-2-phenyl-1,3-thiazole-5-carboximidic acid
NIC02, in combination with NIC04, i.e. 1-benzyl-N-(2,3-dimethylphenyl)-3,5-dimethyl-1H-pyrazole-4-carboxamide
N-(3-[4-hydroxy-1-(3-methylbutyl)-2-oxo-5-[(1E)-pent-1-en-1-yl]-1,2-dihydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl)methanesulfonamide
-
-
N-(3-[4-hydroxy-1-(3-methylbutyl)-2-oxo-5-[(1E)-prop-1-en-1-yl]-1,2-dihydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl)methanesulfonamide
-
-
N-(3-[4-hydroxy-5-[(E)-2-(4-methoxyphenyl)ethenyl]-1-(3-methylbutyl)-2-oxo-1,2-dihydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl)methanesulfonamide
-
-
N-(3-[5-[(1E)-3,3-dimethylbut-1-en-1-yl]-4-hydroxy-1-(3-methylbutyl)-2-oxo-1,2-dihydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl)methanesulfonamide
-
-
N-(4-[[2-(hydroxymethyl)piperidin-1-yl]sulfonyl]phenyl)-1-methyl-4-(trifluoromethyl)-1H-pyrrole-2-carboxamide
-
-
N-(4-[[4-(methoxymethylidene)piperidin-1-yl]sulfonyl]phenyl)-1-methyl-4-(trifluoromethyl)-1H-pyrrole-2-carboxamide
-
-
N-(4-[[4-(tert-butoxyamino)piperazin-1-yl]sulfonyl]phenyl)-1-methyl-4-(trifluoromethyl)-1H-pyrrole-2-carboxamide
-
-
N-propyl-N-[2-(2H-1,2,4-triazino[5,6-b]indol-3-ylthio)ethyl]-1-propanamine
VP32947
N-[(13-cyclohexyl-6,7-dihydroindolo[1,2-d][1,4]benzoxazepin-10-yl)carbonyl]-2-methylalanine
-
-
N-[(1R)-6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl]pyridine-2-carboxamide
-
-
N-[(2,3-difuran-2-ylquinoxalin-6-yl)carbonyl]-5-hydroxy-L-tryptophan
-
N-[(2,3-difuran-2-ylquinoxalin-6-yl)carbonyl]-L-tryptophan
-
N-[(2,3-diphenylquinoxalin-6-yl)carbonyl]-5-hydroxy-L-tryptophan
-
N-[(2,3-diphenylquinoxalin-6-yl)carbonyl]-6-hydroxy-L-tryptophan
-
N-[(2,3-diphenylquinoxalin-6-yl)carbonyl]-L-tryptophan
-
N-[(2,3-dipyridin-2-ylquinoxalin-6-yl)carbonyl]-L-tryptophan
-
N-[(2,3-ditetrahydrofuran-2-ylquinoxalin-6-yl)carbonyl]-6-hydroxy-L-tryptophan
-
N-[(2,3-ditetrahydrofuran-2-ylquinoxalin-6-yl)carbonyl]-L-tryptophan
-
N-[(2,4-dichlorophenyl)carbonyl]-N-[3-(trifluoromethyl)benzyl]-L-phenylalanine
-
-
N-[(2-cyclohexyl-3-phenylquinoxalin-6-yl)carbonyl]-5-hydroxy-L-tryptophan
-
N-[(2-cyclohexyl-3-phenylquinoxalin-6-yl)carbonyl]-L-tryptophan
-
N-[(3-cyclohexyl-2-phenylquinoxalin-6-yl)carbonyl]-5-hydroxy-L-tryptophan
-
N-[(3-cyclohexyl-2-phenylquinoxalin-6-yl)carbonyl]-L-tryptophan
-
N-[(5Z)-5-((5-[2-chloro-5-(trifluoromethyl)phenyl]-2-furyl)methylene)-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]benzenesulfonamide
-
-
N-[(5Z)-5-(3,4-dichlorobenzylidene)-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]benzenesulfonamide
-
-
N-[(5Z)-5-(4-bromobenzylidene)-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]benzenesulfonamide
-
-
N-[(Z)-2-[4-(2-bromophenoxy)phenyl]-1-[(2-hydroxyethyl)carbamoyl]ethenyl]benzamide
-
-
N-[2-amino-4-(pyrrolidin-1-ylsulfonyl)phenyl]-1-methyl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide
-
-
N-[2-hydroxy-4-(pyrrolidin-1-ylsulfonyl)phenyl]-1-methyl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide
-
-
N-[3-[(4aR,7aS)-1-(4-fluorobenzyl)-4-hydroxy-2-oxo-2,4a,5,6,7,7a-hexahydro-1H-cyclopenta[b]pyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[(4R)-1-hydroxy-4-methyl-4-(3-methylbutyl)-3-oxo-3,4-dihydronaphthalen-2-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
A-837093
N-[3-[(4R)-5-(4-fluorobenzyl)-8-hydroxy-4-methyl-6-oxo-5-azaspiro[2.5]oct-7-en-7-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[(5R)-1-cyclobutyl-4-hydroxy-5-methyl-2-oxo-5-propyl-1,2,5,6-tetrahydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[(5R)-1-cyclobutyl-4-hydroxy-5-methyl-5-(3-methylbutyl)-2-oxo-1,2,5,6-tetrahydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[(5R)-1-cyclobutyl-5-(2-cyclopropylethyl)-4-hydroxy-5-methyl-2-oxo-1,2,5,6-tetrahydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[(5R)-1-cyclobutyl-5-(3,3-dimethylbutyl)-4-hydroxy-5-methyl-2-oxo-1,2,5,6-tetrahydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[(5R)-1-cyclohexyl-4-hydroxy-5-methyl-5-(3-methylbutyl)-2-oxo-1,2,5,6-tetrahydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[(5R)-1-cyclohexyl-5-(3,3-dimethylbutyl)-4-hydroxy-5-methyl-2-oxo-1,2,5,6-tetrahydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[(5R)-1-cyclohexyl-5-(4-fluorobenzyl)-4-hydroxy-5-methyl-2-oxo-1,2,5,6-tetrahydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[(5R)-1-cyclopentyl-4-hydroxy-5-(3-methylbut-2-en-1-yl)-2-oxo-1,2,5,6-tetrahydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[(5R)-1-cyclopentyl-4-hydroxy-5-(3-methylbutyl)-2-oxo-1,2,5,6-tetrahydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[(5R)-1-cyclopentyl-4-hydroxy-5-methyl-2-oxo-5-prop-2-yn-1-yl-1,2,5,6-tetrahydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[(5R)-1-cyclopentyl-4-hydroxy-5-methyl-5-(3-methylbutyl)-2-oxo-1,2,5,6-tetrahydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[(5R)-1-cyclopentyl-5-(2-cyclopropylethyl)-4-hydroxy-5-methyl-2-oxo-1,2,5,6-tetrahydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[(5R)-1-cyclopentyl-5-(3,3-dimethylbutyl)-4-hydroxy-5-methyl-2-oxo-1,2,5,6-tetrahydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[(5R)-1-cyclopentyl-5-(4-fluorobenzyl)-4-hydroxy-5-methyl-2-oxo-1,2,5,6-tetrahydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[(5R)-1-cyclopentyl-5-ethyl-4-hydroxy-5-(3-methylbutyl)-2-oxo-1,2,5,6-tetrahydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[(5R)-1-cyclopropyl-4-hydroxy-5-methyl-5-(3-methylbutyl)-2-oxo-1,2,5,6-tetrahydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[(5R)-1-cyclopropyl-5-(3,3-dimethylbutyl)-4-hydroxy-5-methyl-2-oxo-1,2,5,6-tetrahydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[(5R)-1-cyclopropyl-5-(4-fluorobenzyl)-4-hydroxy-5-methyl-2-oxo-1,2,5,6-tetrahydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[(5R)-4-hydroxy-5-methyl-5-(3-methylbutyl)-2-oxo-1-phenyl-1,2,5,6-tetrahydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[(5R)-5-butyl-1-cyclobutyl-4-hydroxy-5-methyl-2-oxo-1,2,5,6-tetrahydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[(5R)-6-(4-fluorobenzyl)-9-hydroxy-5-methyl-7-oxo-6-azaspiro[3.5]non-8-en-8-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[(5S)-1,5-bis(4-fluorobenzyl)-4-hydroxy-2-oxo-1,2,5,6-tetrahydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[(5S)-1-(4-fluorobenzyl)-4-hydroxy-5-(3-methylbut-2-en-1-yl)-2-oxo-1,2,5,6-tetrahydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[(5S)-1-(4-fluorobenzyl)-4-hydroxy-5-(3-methylbutyl)-2-oxo-1,2,5,6-tetrahydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[(5S)-1-(4-fluorobenzyl)-4-hydroxy-5-methyl-2-oxo-5-phenyl-1,2,5,6-tetrahydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[(5S)-1-(4-fluorobenzyl)-4-hydroxy-5-methyl-5-(3-methylbutyl)-2-oxo-1,2,5,6-tetrahydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[(5S)-5-ethyl-1-(4-fluorobenzyl)-4-hydroxy-5-methyl-2-oxo-1,2,5,6-tetrahydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[(5S)-5-tert-butyl-1-(3-chloro-4-fluorobenzyl)-4-hydroxy-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-1,1-dioxido-4H-1,2-benzothiazin-7-yl]methanesulfonamide
-
-
N-[3-[(5S)-5-tert-butyl-1-(4-fluorobenzyl)-4-hydroxy-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-1,1-dioxido-1,2-benzisothiazol-6-yl]methanesulfonamide
-
-
N-[3-[(6R)-1-(4-fluorobenzyl)-4-hydroxy-2-oxo-6-phenyl-1,2,5,6-tetrahydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[(6R)-1-(4-fluorobenzyl)-4-hydroxy-6-(1-methylethyl)-2-oxo-1,2,5,6-tetrahydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[(6R)-1-(4-fluorobenzyl)-4-hydroxy-6-(3-methylbutyl)-2-oxo-1,2,5,6-tetrahydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[(6R)-6-ethyl-1-(4-fluorobenzyl)-4-hydroxy-2-oxo-1,2,5,6-tetrahydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[(6R)-6-tert-butyl-1-(4-fluorobenzyl)-4-hydroxy-2-oxo-1,2,5,6-tetrahydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[(6S)-1-(4-fluorobenzyl)-4-hydroxy-6-(1-methylethyl)-2-oxo-1,2,5,6-tetrahydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[(6S)-1-(4-fluorobenzyl)-6-(4-fluorophenyl)-4-hydroxy-2-oxo-1,2,5,6-tetrahydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[(6S)-6-(1-ethylpropyl)-1-(4-fluorobenzyl)-4-hydroxy-2-oxo-1,2,5,6-tetrahydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[(6S)-6-ethyl-1-(4-fluorobenzyl)-4-hydroxy-2-oxo-1,2,5,6-tetrahydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[1-(4-fluorobenzyl)-4-hydroxy-2-oxo-1,2,5,6-tetrahydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[1-(4-fluorobenzyl)-4-hydroxy-5,5-dimethyl-2-oxo-1,2,5,6-tetrahydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[1-(cyclobutylamino)-4-hydroxy-2-oxo-1,2-dihydroquinolin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]sulfamide
-
-
N-[3-[4-hydroxy-1-(3-methylbutyl)-2-oxo-1,2-dihydro-1,8-naphthyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
-
N-[3-[4-hydroxy-1-(3-methylbutyl)-2-oxo-1,2-dihydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
-
N-[3-[4-hydroxy-1-(3-methylbutyl)-2-oxo-5-phenyl-1,2-dihydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
-
N-[3-[4-hydroxy-1-(3-methylbutyl)-2-oxo-5-thiophen-2-yl-1,2-dihydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
-
N-[3-[5-acetyl-4-hydroxy-1-(3-methylbutyl)-2-oxo-1,2-dihydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
-
N-[3-[5-bromo-4-hydroxy-1-(3-methylbutyl)-2-oxo-1,2-dihydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
-
N-[3-[5-ethenyl-4-hydroxy-1-(3-methylbutyl)-2-oxo-1,2-dihydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
-
N-[3-[5-furan-2-yl-4-hydroxy-1-(3-methylbutyl)-2-oxo-1,2-dihydropyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
-
N-[3-[6-(4-fluorobenzyl)-9-hydroxy-7-oxo-6-azaspiro[4.5]dec-8-en-8-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[3-[7-(4-fluorobenzyl)-10-hydroxy-8-oxo-7-azaspiro[4.5]dec-9-en-9-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
-
N-[4-(1H-indol-1-ylsulfonyl)phenyl]-1-methyl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide
-
-
N-[4-(1H-indol-1-ylsulfonyl)phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-2-carboxamide
-
-
N-[4-(azepan-1-ylsulfonyl)phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-2-carboxamide
-
-
N-[4-(azocan-1-ylsulfonyl)phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-2-carboxamide
-
-
N-[4-(cyclohexylsulfamoyl)phenyl]-1-methyl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide
-
-
N-[4-(diethylsulfamoyl)phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-2-carboxamide
-
-
N-[4-(dimethylsulfamoyl)phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-2-carboxamide
-
-
N-[4-(diprop-2-en-1-ylsulfamoyl)phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-2-carboxamide
-
-
N-[4-(dipropylsulfamoyl)phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-2-carboxamide
-
-
N-[4-(pyrrolidin-1-ylsulfonyl)phenyl]-1,3-benzothiazole-2-carboxamide
-
-
N-[4-(pyrrolidin-1-ylsulfonyl)phenyl]-1-[2-(trifluoromethyl)phenyl]-1H-imidazole-2-carboxamide
-
-
N-[4-(pyrrolidin-1-ylsulfonyl)phenyl]-2-(trifluoromethyl)benzamide
-
-
N-[4-(pyrrolidin-1-ylsulfonyl)phenyl]-3-(trifluoromethyl)benzamide
-
-
N-[4-(pyrrolidin-1-ylsulfonyl)phenyl]-4-(trifluoromethyl)benzamide
-
-
N-[4-(pyrrolidin-1-ylsulfonyl)phenyl]furan-2-carboxamide
-
-
N-[4-(pyrrolidin-1-ylsulfonyl)phenyl]thiophene-2-carboxamide
-
-
N-[4-([4-[2-(2-hydroxyethoxy)ethyl]piperazin-1-yl]sulfonyl)phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-2-carboxamide
-
-
N-[4-[(2,6-dimethylpiperidin-1-yl)sulfonyl]phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-2-carboxamide
-
-
N-[4-[(2-ethylpiperidin-1-yl)sulfonyl]phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-2-carboxamide
-
-
N-[4-[(4-aminopiperidin-1-yl)sulfonyl]phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-2-carboxamide
-
-
N-[4-[(4-hydroxypiperidin-1-yl)sulfonyl]phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-2-carboxamide
-
-
N-[4-[(4-tert-butoxypiperazin-1-yl)sulfonyl]phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-2-carboxamide
-
-
N-[4-[bis(1-methylethyl)sulfamoyl]phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-2-carboxamide
-
-
N-[4-[bis(2-methylpropyl)sulfamoyl]phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-2-carboxamide
-
-
N-[[(1S,9aR)-9a-methyloctahydro-2H-quinolizin-1-yl]methyl]-4-[(E)-phenyldiazenyl]-5,6,7,8-tetrahydronaphthalen-1-amine}
N-[[(1S,9aR)-9a-methyloctahydro-2H-quinolizin-1-yl]methyl]-4-[(E)-[3-(trifluoromethyl)phenyl]diazenyl]-5,6,7,8-tetrahydronaphthalen-1-amine}
N-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]methyl]-4-(pyrrolidin-1-ylsulfonyl)aniline
-
-
N-[[2,3-bis(3-methoxyphenyl)quinoxalin-6-yl]carbonyl]-6-hydroxy-L-tryptophan
-
N-[[2,3-bis(3-methoxyphenyl)quinoxalin-6-yl]carbonyl]-L-tryptophan
-
N-[[2,3-bis(4-fluorophenyl)quinoxalin-6-yl]carbonyl]-5-(carboxymethoxy)-L-tryptophan
-
N-[[2,3-bis(4-fluorophenyl)quinoxalin-6-yl]carbonyl]-5-hydroxy-L-tryptophan
-
N-[[2,3-bis(4-fluorophenyl)quinoxalin-6-yl]carbonyl]-5-[[(2E)-3-carboxyprop-2-en-1-yl]oxy]-L-tryptophan
-
N-[[2,3-bis(4-fluorophenyl)quinoxalin-6-yl]carbonyl]-6-(carboxymethoxy)-L-tryptophan
-
N-[[2,3-bis(4-fluorophenyl)quinoxalin-6-yl]carbonyl]-6-hydroxy-L-tryptophan
-
N-[[2,3-bis(4-fluorophenyl)quinoxalin-6-yl]carbonyl]-6-[[(2E)-3-carboxyprop-2-en-1-yl]oxy]-L-tryptophan
-
N-[[2,3-bis(4-fluorophenyl)quinoxalin-6-yl]carbonyl]-L-tryptophan
-
N-[[2,3-bis(4-methylphenyl)quinoxalin-6-yl]carbonyl]-5-hydroxy-L-tryptophan
-
N-[[2,3-bis(4-methylphenyl)quinoxalin-6-yl]carbonyl]-6-hydroxy-L-tryptophan
-
N-[[2,3-bis(4-methylphenyl)quinoxalin-6-yl]carbonyl]-L-tryptophan
-
N-[[2-cyclohexyl-3-(4-fluorophenyl)quinoxalin-6-yl]carbonyl]-5-hydroxy-L-tryptophan
-
N-[[2-cyclohexyl-3-(4-fluorophenyl)quinoxalin-6-yl]carbonyl]-L-tryptophan
-
N-[[3-cyclohexyl-2-(4-fluorophenyl)quinoxalin-6-yl]carbonyl]-5-hydroxy-L-tryptophan
-
N-[[3-cyclohexyl-2-(4-fluorophenyl)quinoxalin-6-yl]carbonyl]-L-tryptophan
-
N2-[3-[4-hydroxy-1-(3-methylbutyl)-2-oxo-1,2-dihydro-1,8-naphthyridin-3-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl]glycinamide
-
-
NADPH
NEM
-
0.1 mM, reduces the transcription activity down to 10%
NTP
-
3Dpol is inhibited by NTP concentrations higher than 2 mM
p-Hydroxymercuriphenylsulfonate
-
0.1 mM, reduces the transcription activity down to 10%
pancreatic RNase
-
0.006 mg/ml, marked inhibition
-
PCMB
-
inhibition is reversed by incubation with an excess amount of dithiothreitol and 2-mercaptoethanol. PCMB-inhibited enzyme is unable to synthesize RNA, but still maintains template-binding ability
phenyl 1-[[4-([[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]carbonyl]amino)phenyl]sulfonyl]-L-prolinate
-
-
phenylalanine
binding of non-nucleoside inhibitors induces significant fluctuations at the atomic level which are critical for enzymatic activity, with minimalglobal structural alterations. Residue-wise mapping of interactions of non-nucleoside inhibitors at different sites exhibits some conserved interaction patterns of key amino acids and water molecules
Poly(U)
-
inhibits by competing with the template for binding to the enzyme, does not inhibit the elongation of preinitiated RNA chains
Polyarginine
-
strong
Polyethylene sulfonate
-
inhibits by competing with the template for binding to the enzyme, does not inhibit the elongation of preinitiated RNA chains
-
polylysine
Polyornithine
-
strong
ppGpp
propan-2-yl (2S)-2-([([(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxy-4-(prop-1-yn-1-yl)oxolan-2-yl]methoxy)(phenoxy)phosphoryl]amino)propanoate
-
-
propan-2-yl (2S)-2-([([(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy)(phenoxy)phosphoryl]amino)propanoate
-
-
propan-2-yl (2S)-2-([([(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-ethynyl-3,4-dihydroxyoxolan-2-yl]methoxy)(phenoxy)phosphoryl]amino)propanoate
-
-
propan-2-yl (2S)-2-([([(2S,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-fluoro-3,4-dihydroxy-4-(prop-1-yn-1-yl)oxolan-2-yl]methoxy)(phenoxy)phosphoryl]amino)propanoate
-
-
propan-2-yl (2S)-2-([([(2S,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-fluoro-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy)(phenoxy)phosphoryl]amino)propanoate
-
-
propan-2-yl (2S)-2-([([(2S,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-ethynyl-2-fluoro-3,4-dihydroxyoxolan-2-yl]methoxy)(phenoxy)phosphoryl]amino)propanoate
-
the prodrug displays potent anti-dengue virus activity in the primary human peripheral blood mononuclear cell-based assay with no significant cytotoxicity in human hepatocellular liver carcinoma cell lines and no mitochondrial toxicity in the cell-based assay using human prostate cancer cell lines
pyrogallol
-
-
quercetin
high affinities with the RNA-polymerase active site; strong binding affinity to the enzyme (RdRp)
quercetin-3'-O-glucuronide
better binding affinities than quercetin
quercetin-3'-O-sulfate
better binding affinities than quercetin
quercetin-3-O-glucoside
strong binding affinity to the enzyme (RdRp)
quercetin-3-O-glucuronide
better binding affinities than quercetin
quercetin-3-O-rutinoside
i.e. rutin, most active compared to all quercetin derivatives
quercetin-7-O-glucuronide
better binding affinities than quercetin
quercetin-7-O-sulfate
better binding affinities than quercetin
quercitrin
strong binding affinity to the enzyme (RdRp)
quinupristin
virtual screen identifies several drugs predicted to bind in the conserved RNA tunnel. Quinupristin is expected to bind across the RNA tunnel, blocking access from both sides and suggesting that it has the potential to arrest viral replication by preventing viral RNA synthesis. Quinupristin is an antibiotic that has been in clinical use for two decades and causes relatively minor side effects
R7128
is the prodrug of PSI-6130, inhibits the enzyme and viral replication
remdesivir
remdesivir triphosphate
ribavirin
ribosomal RNA
-
-
RNA
-
inhibited by high non-template RNA concentrations. This inhibition indicates feedback regulation of minus-strand synthesis
RNase
-
setrobuvir
high potential to fight the SARS-CoV-2 strain specifically
Sodium diphosphate
-
10 mM, decreases incorporation down to 5%
sofosbuvir
sofosbuvir triphosphate
spermine
suramin
Tenofovir
binds to the enzyme (SARS-CoV-2 RdRp) with binding energies comparable to native nucleotides, potent drugs against SARS-CoV-2
tert-butyl 1-[[4-([[1-methyl-4-(trifluoromethyl)-1H-pyrrol-2-yl]carbonyl]amino)phenyl]sulfonyl]piperidine-2-carboperoxoate
-
-
tetracyclic indole inhibitors
-
thiazolone inhibitors
-
thiophene
binding of non-nucleoside inhibitors induces significant fluctuations at the atomic level which are critical for enzymatic activity, with minimalglobal structural alterations. Residue-wise mapping of interactions of non-nucleoside inhibitors at different sites exhibits some conserved interaction patterns of key amino acids and water molecules
tipranavir
binds to RNA-dependent RNA polymerase with high affinity
Y27632
-
blocks HCV RdRp phosphorylation by suppressing PRK2 activation, reduces the levels of intracellular viral RNA by 92% at 0.02 mM, the RdRp activity of HCV NS5B is not inhibited by the PRK2 inhibitor, but its activation by phosphorylation through PRK2
YAK
high potential to fight the SARS-CoV-2 strain specifically
[(1R)-5-cyano-8-methyl-1-propyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl]acetic acid
-
-
[(1R)-8-chloro-5-ethyl-1-propyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl]acetic acid
-
-
[(1S)-5-cyano-8-methyl-1-(1-methylpropyl)-7-[2-(1H-pyrazol-1-yl)ethoxy]-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl]acetic acid
-
-
[(2Z)-2-(3,4,5-trihydroxybenzylidene)hydrazino]acetic acid
-
-
[N,N-dimethyl-N'-(4-phenylazophenyl)]propane-1,3-diamine
additional information
-